Helix, a leader in precision health, is unveiling a new comprehensive clinico-genomic dataset of over 15,000 patients treated with glucagon-like-peptide-1 (GLP-1) agonists including semaglutide, tirzepatide, liraglutide, dulaglutide and many others.

The research-ready Virtual Registry was built as part of the Helix Research Network (HRN). The cohort consists of whole Exome+^® sequencing profiles for 15,000 GLP-1 agonist treated patients combined with longitudinal and regularly refreshed EHR data including demographics, clinical diagnosis (T2D, CVD, kidney diseases, etc), major lab results, procedures, and insights from medical and mortality claims data.

"The success of GLP-1 agonists like semaglutide and tirzepatide have created incredible advances in the treatment of cardiometabolic disease and obesity, and the demand for and uptake of these therapies are not slowing down anytime soon," said James Lu, M.D., Ph.D., CEO of Helix. "Our registry has more than tripled in less than a year, and will continue to meet and even outpace usage trends, allowing insights from deep real-world data coupled with broad genomic data to play a key role in monitoring safety profiles, determining cost-effectiveness, and improving treatment efficacy in select populations."

At the recent ASHG 2024 Annual Meeting, Helix researchers unveiled a groundbreaking novel precision effectiveness model that predicts the weight loss response of semaglutide in diverse populations, which was made possible by the GLP-1 agonist HRN data. The study found that integrating a polygenic risk score with co-morbid factors, such as the presence of type 2 diabetes and hypertension, could predict the 12-month weight loss response to semaglutide treatment in individuals.